Performance of NUVB Nuvation Bio | 103.7% in 12m
Compare NUVB with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Nuvation Bio with its related Sector/Index XBI
Performance Duell NUVB vs XBI
| TimeFrame | NUVB | XBI |
|---|---|---|
| 1 Day | -2.64% | -1.52% |
| 1 Week | -1.48% | 1.45% |
| 1 Month | 27.7% | 10.08% |
| 3 Months | 86.5% | -1.30% |
| 6 Months | 145.9% | 24.09% |
| 12 Months | 103.7% | 6.83% |
| YTD | 111.5% | 1.05% |
| Rel. Perf. 1m | 1.39 | |
| Rel. Perf. 3m | 7.71 | |
| Rel. Perf. 6m | 6.51 | |
| Rel. Perf. 12m | 6.66 |
Is Nuvation Bio a good stock to buy?
Probably not. Based on ValueRay Analyses, Nuvation Bio (NYSE:NUVB) is currently (May 2024)
not a good stock to buy. It has a ValueRay Growth Rating of -4.12 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NUVB as of May 2024 is 3.65. This means that NUVB is currently overvalued and has a potential downside of 9.94% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NUVB as of May 2024 is 3.65. This means that NUVB is currently overvalued and has a potential downside of 9.94% (Sold with Premium).
Is NUVB a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
Values above 0%: NUVB is performing better - Values below 0%: NUVB is underperforming
Compare NUVB with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -3.12% | 20.76% | 128.54% | 75.37% |
| US NASDAQ 100 | QQQ | -3.44% | 18.74% | 129.87% | 68.53% |
| US Dow Jones Industrial 30 | DIA | -2.87% | 22.23% | 131.15% | 81.77% |
| German DAX 40 | DBXD | -1.24% | 22.54% | 128.77% | 89.30% |
| UK FTSE 100 | ISFU | -3.02% | 18.14% | 129.69% | 89.03% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -2.63% | 22.96% | 143.81% | 110.96% |
| Hongkong Hang Seng | HSI | -3.63% | 4.83% | 142.24% | 109.09% |
| Japan Nikkei 225 | EXX7 | -2.54% | 26.81% | 134.15% | 92.95% |
| India NIFTY 50 | INDA | -3.90% | 24.49% | 128.35% | 73.86% |
| Brasil Bovespa | EWZ | -1.39% | 24.40% | 149.69% | 90.97% |
NUVB Nuvation Bio vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -2.67% | 23.74% | 128.75% | 67.90% |
| Consumer Discretionary | XLY | -1.95% | 22.42% | 139.14% | 84.85% |
| Consumer Staples | XLP | -2.53% | 22.63% | 131.61% | 97.65% |
| Energy | XLE | -2.95% | 27.70% | 131.97% | 80.32% |
| Financial | XLF | -3.47% | 22.46% | 124.00% | 71.02% |
| Health Care | XLV | -3.47% | 22.39% | 131.62% | 90.43% |
| Industrial | XLI | -1.62% | 23.66% | 126.60% | 75.97% |
| Materials | XLB | -1.88% | 24.10% | 130.11% | 84.08% |
| Real Estate | XLRE | -3.72% | 19.66% | 137.13% | 92.82% |
| Technology | XLK | -4.05% | 17.67% | 131.27% | 68.08% |
| Utilities | XLU | -2.98% | 17.13% | 127.37% | 90.49% |
| Aerospace & Defense | XAR | -2.55% | 19.33% | 131.68% | 79.25% |
| Biotech | XBI | -2.93% | 17.61% | 121.84% | 96.85% |
| Homebuilder | XHB | -2.06% | 20.69% | 115.67% | 52.83% |
| Retail | XRT | -1.00% | 21.00% | 125.83% | 74.18% |
Does Nuvation Bio outperform its market, is NUVB a Sector Leader?
Yes, over the last 12 months Nuvation Bio (NUVB) made 103.68%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.83%.
Over the last 3 months NUVB made 86.52%, while XBI made -1.30%.
Yes, over the last 12 months Nuvation Bio (NUVB) made 103.68%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.83%.
Over the last 3 months NUVB made 86.52%, while XBI made -1.30%.
| Period | NUVB | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 27.69% | 10.08% | 6.93% |
| 3 Months | 86.52% | -1.30% | 6.91% |
| 12 Months | 103.68% | 6.83% | 28.31% |